FI104234B1 - Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon - Google Patents
Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoonInfo
- Publication number
- FI104234B1 FI104234B1 FI924605A FI924605A FI104234B1 FI 104234 B1 FI104234 B1 FI 104234B1 FI 924605 A FI924605 A FI 924605A FI 924605 A FI924605 A FI 924605A FI 104234 B1 FI104234 B1 FI 104234B1
- Authority
- FI
- Finland
- Prior art keywords
- treatment
- antibody conjugates
- neoplastic diseases
- producing antibody
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
- A61K47/6823—Double chain ricin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51092390A | 1990-04-19 | 1990-04-19 | |
| US51092390 | 1990-04-19 | ||
| PCT/US1991/002696 WO1991016071A1 (en) | 1990-04-19 | 1991-04-19 | Antibody conjugates for treatment of neoplastic disease |
| US9102696 | 1991-04-19 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI924605A FI924605A (fi) | 1992-10-12 |
| FI924605A0 FI924605A0 (fi) | 1992-10-12 |
| FI104234B FI104234B (fi) | 1999-12-15 |
| FI104234B1 true FI104234B1 (fi) | 1999-12-15 |
Family
ID=24032743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI924605A FI104234B1 (fi) | 1990-04-19 | 1992-10-12 | Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20050214307A1 (ru) |
| EP (1) | EP0525119B1 (ru) |
| JP (1) | JP3340127B2 (ru) |
| KR (1) | KR100212372B1 (ru) |
| CN (1) | CN1071579C (ru) |
| AT (1) | ATE164078T1 (ru) |
| AU (1) | AU650267B2 (ru) |
| CA (1) | CA2079902C (ru) |
| DE (1) | DE69129109T2 (ru) |
| DK (1) | DK0525119T3 (ru) |
| ES (1) | ES2113376T3 (ru) |
| FI (1) | FI104234B1 (ru) |
| HK (1) | HK1008418A1 (ru) |
| IE (1) | IE62496B1 (ru) |
| IL (1) | IL97776A (ru) |
| NO (1) | NO317485B1 (ru) |
| NZ (1) | NZ237688A (ru) |
| PT (1) | PT97423B (ru) |
| RU (1) | RU2119352C1 (ru) |
| SA (1) | SA91120208B1 (ru) |
| TW (1) | TW211573B (ru) |
| WO (1) | WO1991016071A1 (ru) |
| ZA (1) | ZA912490B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| CA2072249C (en) * | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US6787153B1 (en) | 1991-06-28 | 2004-09-07 | Mitsubishi Chemical Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US5632982A (en) * | 1994-06-07 | 1997-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic enhancement of TNF with copper |
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| US7101977B2 (en) * | 2001-07-17 | 2006-09-05 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| CA2488858A1 (en) * | 2002-06-12 | 2003-12-24 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
| WO2004037209A2 (en) * | 2002-10-25 | 2004-05-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | METHODS TO PREVENT TUMOR RECURRENCE BY BLOCKADE OF TGF-β |
| WO2006083961A2 (en) * | 2005-02-01 | 2006-08-10 | Research Development Foundation | Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders |
| CA2598090A1 (en) * | 2005-02-17 | 2006-08-24 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Synergistic effect of tgf-beta blockade and immunogenic agents on tumors |
| CA2646127A1 (en) * | 2006-03-16 | 2007-09-27 | Health Research Inc. | Inhibition of breast carcinoma stem cell growth and metastasis |
| RU2014148162A (ru) | 2012-05-01 | 2016-06-20 | Дженентек, Инк. | Анти-pmel17 антитела и их иммуноконъюгаты |
| RU2670748C9 (ru) * | 2013-06-24 | 2018-12-13 | Аблбио | Конъюгаты антител с лекарственными агентами, обладающие улучшенной стабильностью, и их применение |
| KR102318994B1 (ko) | 2015-01-23 | 2021-10-29 | 헬릭스 바이오파마 코포레이션 | 치료학적 목적을 위한 항체-우레아제 접합체 |
| MY195280A (en) | 2017-09-08 | 2023-01-12 | New Portal Ltd | Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability |
| CN110455903A (zh) * | 2018-05-07 | 2019-11-15 | 天士力生物医药股份有限公司 | 一种注射用重组人尿激酶原杂质分析的梯度电泳检测方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4263279A (en) * | 1975-08-19 | 1981-04-21 | Yeda Research & Development Co. Ltd | Pharmaceutically active compositions containing adriamycin and daunomycin |
| FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4522918A (en) * | 1981-12-15 | 1985-06-11 | Jeffery Schlom | Process for producing monoclonal antibodies reactive with human breast cancer |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| FR2546756B1 (fr) * | 1983-06-03 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux derives immunostimulants, leur preparation et leur application comme medicament |
| US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
| US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
| US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| US4677064A (en) * | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US5032521A (en) * | 1984-12-05 | 1991-07-16 | The Salk Institute For Biological Studies | Monoclonal antibody specific for a mammary tumor cell surface antigen |
| US4888415A (en) * | 1985-03-04 | 1989-12-19 | Dana-Farber Cancer Institute, Inc. | Gelonin immunotoxin |
| US6084073A (en) * | 1985-03-25 | 2000-07-04 | Chiron Corporation | Recombinant ricin toxin |
| US4870163A (en) * | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4962188A (en) * | 1985-12-06 | 1990-10-09 | Cetus Corporation | Recombinant ricin toxin A chain conjugates |
| US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
| US4894227A (en) * | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| US4894225A (en) * | 1987-03-02 | 1990-01-16 | Cetus Corporation | Combination therapy using antitumor immunotoxins with tumor necrosis factor |
| US4863726A (en) * | 1987-05-29 | 1989-09-05 | Cetus Corporation | Combination therapy using immunotoxins with interleukin-2 |
| US5017371A (en) * | 1988-01-06 | 1991-05-21 | Amarillo Cell Culture Company, Incorporated | Method for reducing side effects of cancer therapy |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
| ZA902949B (en) * | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| US6306626B1 (en) * | 1990-04-27 | 2001-10-23 | Research Development Foundation | Anti-IgM monoclonal antibodies and methods of their use |
| IE912716A1 (en) * | 1990-08-14 | 1992-02-26 | Res Dev Foundation | Protein Structure of the Plant Toxin Gelonin |
| US6099842A (en) * | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
| CA2074825C (en) * | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
| US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
| IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
| US5513296A (en) * | 1994-06-08 | 1996-04-30 | Holmes Products Corp. | Air heater with angled PTC heaters producing diverging heated airflow |
| WO1999051620A1 (en) * | 1998-04-03 | 1999-10-14 | Invitrogen Corporation | Libraries of expressible gene sequences |
| US20030186384A1 (en) * | 2000-04-22 | 2003-10-02 | Stefan Barth | Apoptotic agents |
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| US7101977B2 (en) * | 2001-07-17 | 2006-09-05 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| CA2488858A1 (en) * | 2002-06-12 | 2003-12-24 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
-
1991
- 1991-04-04 IE IE112291A patent/IE62496B1/en not_active IP Right Cessation
- 1991-04-04 ZA ZA912490A patent/ZA912490B/xx unknown
- 1991-04-04 NZ NZ237688A patent/NZ237688A/xx unknown
- 1991-04-04 IL IL9777691A patent/IL97776A/xx not_active IP Right Cessation
- 1991-04-12 TW TW080102833A patent/TW211573B/zh active
- 1991-04-19 WO PCT/US1991/002696 patent/WO1991016071A1/en active IP Right Grant
- 1991-04-19 ES ES91909732T patent/ES2113376T3/es not_active Expired - Lifetime
- 1991-04-19 RU RU92016354A patent/RU2119352C1/ru not_active IP Right Cessation
- 1991-04-19 PT PT97423A patent/PT97423B/pt not_active IP Right Cessation
- 1991-04-19 AU AU78922/91A patent/AU650267B2/en not_active Ceased
- 1991-04-19 DK DK91909732T patent/DK0525119T3/da active
- 1991-04-19 CN CN91102606A patent/CN1071579C/zh not_active Expired - Fee Related
- 1991-04-19 KR KR1019920702569A patent/KR100212372B1/ko not_active IP Right Cessation
- 1991-04-19 DE DE69129109T patent/DE69129109T2/de not_active Expired - Fee Related
- 1991-04-19 AT AT91909732T patent/ATE164078T1/de not_active IP Right Cessation
- 1991-04-19 CA CA002079902A patent/CA2079902C/en not_active Expired - Fee Related
- 1991-04-19 EP EP91909732A patent/EP0525119B1/en not_active Expired - Lifetime
- 1991-04-19 JP JP50922891A patent/JP3340127B2/ja not_active Expired - Fee Related
- 1991-10-23 SA SA91120208A patent/SA91120208B1/ar unknown
-
1992
- 1992-10-12 FI FI924605A patent/FI104234B1/fi not_active IP Right Cessation
- 1992-10-16 NO NO19924025A patent/NO317485B1/no unknown
-
1998
- 1998-07-14 HK HK98109132A patent/HK1008418A1/xx not_active IP Right Cessation
-
2004
- 2004-08-26 US US10/926,731 patent/US20050214307A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI104234B1 (fi) | Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon | |
| NO885199D0 (no) | Fremgangsmte for fremstilling av monoklonale antistoffkonjugater. | |
| PL248202A1 (en) | Process for preparing conjugate with chain b of toxin and method of manufacture of cytotoxic composition | |
| AU563356B2 (en) | Conjugate of enzyme and antibody | |
| RU92016354A (ru) | Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата | |
| EP1594542A4 (en) | ANTI-CD70 ANTIBODY MEDICAMENT CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | |
| NO175964C (no) | Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning | |
| BG42837A3 (en) | Method for preparing immunoglobulin derivatives of vinka alkaloides | |
| NZ210867A (en) | Tumour-specific monoclonal antibodies, production thereof and use | |
| FI880059A0 (fi) | Foerfarande foer framstaellning av antikroppkonjugater av folsyraanalogers aminderivat. | |
| GB1446536A (en) | Pharmaceutically active compositions | |
| HUT43495A (en) | Process for production and compound for treating of cancer and beningn tumor | |
| WO2004041307A3 (en) | Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy | |
| TWI265811B (en) | Extended type 1 chain glycosphingolipids as tumor-associated antigens | |
| HU9202219D0 (en) | Method for producing conjugated compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |